LPL's Role in Disease Development (G4023)

Target Name: LPL

NCBI ID: G4023

Content of Review Report on LPL Target / Biomarker

LPL

LPL's Role in Disease Development

LPL (Low-Platelet Count) is a protein that is expressed in the liver and other tissues. It is a key regulator of hematopoietic stem cell proliferation and has been implicated in a number of diseases, including liver disease and cancer.

Recent studies have suggested that LPL may be a drug target or biomarker for a number of diseases, including cancer, cardiovascular disease, and neurological disorders. This is because LPL has been shown to play a role in the regulation of cellular processes that are important for the development and progression of these diseases.

One potential mechanism by which LPL may be involved in the development of cancer is by regulating the production of blood cells that are responsible for fighting off infections and repairing damaged tissue. Many cancer cells are able to evade the immune system by manipulating these cellular processes, and LPL may be one of the keys that allows them to do so.

In addition, LPL has been shown to play a role in the regulation of cellular signaling pathways that are important for the development of many diseases, including cancer. Many of these signaling pathways involve the production and deployment of signaling proteins, and LPL may be involved in regulating the production and localization of these proteins.

Another potential mechanism by which LPL may be involved in the development of cardiovascular disease is by regulating the production of immune cells that are responsible for fighting off infections and promoting tissue repair. Many cardiovascular diseases, including heart failure and hypertension, are caused by the failure of these immune cells to function properly, and LPL may be one of the keys that allows these diseases to occur.

In addition, LPL has been shown to play a role in the regulation of cellular processes that are important for the development and progression of neurological disorders. Many of these disorders, including Alzheimer's disease and Parkinson's disease, are caused by the dysfunction of immune cells and LPL may be involved in regulating the production and localization of these cells.

Overall, LPL is a protein that has been shown to play a role in a number of diseases and may be a potential drug target or biomarker. Further research is needed to fully understand the role of LPL in these diseases and to develop effective treatments.

Protein Name: Lipoprotein Lipase

Functions: Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage (PubMed:8675619, PubMed:11342582, PubMed:27578112). Although it has both phospholipase and triglyceride lipase activities it is primarily a triglyceride lipase with low but detectable phospholipase activity (PubMed:7592706, PubMed:12032167). Mediates margination of triglyceride-rich lipoprotein particles in capillaries (PubMed:24726386). Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans (PubMed:11342582, PubMed:27811232)

The "LPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets